Selective FXIa Inhibitor for Safer Anticoagulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulant drugs, particularly FXa inhibitors, are associated with a high risk of bleeding complications, necessitating the development of safer alternatives that effectively prevent thromboembolic disorders with minimal bleeding side effects.
Innovation Solution
A novel compound represented by formula (I), its optical isomer, and pharmaceutically acceptable salts, which act as a selective FXIa inhibitor, are developed to target the coagulation cascade, potentially offering a safer antithrombotic profile compared to existing FXa inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FXa inhibitors are used to prevent thromboembolic disorders, then efficacy in preventing thrombosis is improved, but bleeding risk increases
Solution Approach 1:
The patent changes the target parameter from FXa to FXIa in the coagulation cascade. By developing selective FXIa inhibitors instead of FXa inhibitors, the invention modifies the intervention point in the coagulation pathway to achieve thromboprophylaxis with reduced bleeding risk, as FXIa plays a less critical role in hemostasis compared to FXa
Solution Approach 2:
The invention introduces FXIa as an intermediary target between thrombin and FXa in the coagulation cascade. By inhibiting FXIa, the patent blocks the amplification loop of the coagulation cascade indirectly, achieving antithrombotic effect while preserving some degree of physiological hemostasis that would be completely blocked by direct FXa or thrombin inhibition
2Reliability
If traditional anticoagulant drugs are used, then thrombosis prevention is achieved, but bleeding complications increase
Solution Approach 1:
The patent changes the therapeutic parameter from non-selective anticoagulation to selective FXIa inhibition. This parameter change allows for targeted intervention in the coagulation cascade at a point that is less critical for hemostasis, thereby maintaining thrombosis prevention efficacy while reducing bleeding complications
Solution Approach 2:
The invention segments the coagulation cascade into distinct targetable pathways and selects FXIa as the specific target. By dividing the complex coagulation system into manageable segments and selecting a less critical segment (FXIa) for inhibition, the patent achieves thromboprophylaxis with a better safety profile regarding bleeding complications
Data Source
AI summary
A compound represented by formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, as well as an application of said compound as an FXIa inhibitor.